Preventing post-ERCP pancreatitis: Where are we?

Journal of the Pancreas

Volumn 4, Issue 1, 2003, Pages 22-32

  Testoni, Pier Alberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Acute disease; Cholangiopancreatography, cost benefit analysis; Endoscopic retrograde; Endoscopy; Pancreas; Pancreatitis, acute necrotizing; Preventive medicine; Primary prevention; Risk factors; Sphincterotomy, endoscopic

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; GABEXATE MESILATE; HEPARIN; LYSOSOME ENZYME; NIFEDIPINE; OCTREOTIDE; PANCREAS ENZYME; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 10; SOMATOSTATIN; TRYPSIN; TRYPSINOGEN;

ACUTE PANCREATITIS; ARTICLE; BALLOON DILATATION; CANNULATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SURGERY; ENZYME INHIBITION; ENZYME LOCALIZATION; HIGH RISK PATIENT; HUMAN; HYPERAMYLASEMIA; INCIDENCE; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; ODDI SPHINCTER; PANCREAS DUCT; PATIENT SELECTION; RADIOLOGIST; RISK FACTOR; STENT; VATER PAPILLA; VATER PAPILLOTOMY; ANIMAL; ECONOMICS; META ANALYSIS; METHODOLOGY; MULTICENTER STUDY; PANCREATITIS; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

ANIMALS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; HUMANS; META-ANALYSIS; MULTICENTER STUDIES; PANCREATITIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0037264489     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Gottlieb K, Sherman S. ERCP and endoscopic biliary sphincterotomy-induced pancreatitis. Gastrointest Clin N Am 1998; 8:87-114. [AN 98070870]
2. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54:425-34. [AN 21460528]
3. Akashi R, Kiyozumi T, Tanaka T, Sakurai K, Oda Y, Sagara K. Mechanism of pancreatitis caused by ERCP. Gastrointest Endosc 2002; 55:50-4. [AN 21629113]
4. Tarnasky PR, Palesch YY, Cunningham JT, Mauldin PD, Cotton PB, Hawes RH. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998; 115:1518-24. [AN 99055594]
5. Fogel EL, Eversman D, Jamidar P, Sherman S, Lehman GA. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy 2002; 34:280-5. [AN 21929640]
6. Patel R, Tarnasky PR, Hennessy WS, et al. Does stenting after pancreatic sphincterotomy reduce post-ERCP pancreatitis in patients with prior biliary sphincterotomy? Preliminary results of a prospective, randomized trial. Gastrointest Endosc 1999; 49:A80.
7. Aizawa T, Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. Gastrointest Endosc 2001; 54:209-13. [AN 21367702]
8. Smithline A, Silverman W, Rogers D, Nisi R, Wiersema M, Jamidar P, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993; 39:652-7. [AN 94040541]
9. Skude G, Wehlin L, Maruyama T, Ariyama J. Hyperamylasaemia after duodenoscopy and retrograde cholangiopancreatography. Gut 1976; 17:127-32. [AN 76166167]
10. Lella F, Bagnolo F, Colombo E, Bonassi U, Caporuscio S, Elia S, et al. Guide-wire cannulation of Vater's papilla for detecting the main biliary duct during ERCP: a valid and effective method to avoid post-procedural pancreatitis. Gastrointest Endosc 2000; 51:AB71.
11. Bockman DE, Schiller WR, Anderson MC. Route of retrograde flow in the exocrine pancreas during ductal hypertension. Arch Surg 1971; 103:321-9. [AN 71263087]
12. Tulassay Z, Papp J, Koranyi L, Szathmari M, Tamas G Jr. Hormonal and biochemical changes following endoscopic retrograde cholangiopancreatography. Acta Gastroenterol Belg 1981; 44:538-44. [AN 82280344]
13. Kasugai T, Kuno N, Kizu M. Manometric endoscopic retrograde pancreatography: technique, significance and evaluation. Am J Dig Dis 1974; 19:485-502. [AN 74167051]
14. Kivisaari L. Contrast absorption and pancreatic inflammation following experimental ERCP. Invest Radiol 1979; 14:493-7. [AN 80114806]
15. Okuno M, Himeno S, Kurokawa M, Shinomura Y, Kuroshima T, Kanayama S, e al. Changes in serum levels of pancreatic isoamylase, lipase, trypsin, and elastase 1 after endoscopic retrograde pancreatography. Hepatogastroenterology 1985; 32:87-90. [AN 85232697]
16. Lavelle MI, Tait NP, Walsh T, Alderson D, Record CO. Demonstration of pancreatic parenchyma by digital subtraction techniques during endoscopic retrograde cholangiopancreatography. Clin Radiol 1985; 36:405-7 [AN 86054500]
17. Johnson GK, Geenen JE, Bedford RA, Johanson J, Cass O, Sherman S, et al. A comparison of nonionic versus ionic contrast media: results of a prospective multicenter study. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc 1995; 42:312-6. [AN 96121321]
18. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-18. [AN 96365275]
19. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1-10. [AN 98347799]
20. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417-23. [AN 21122345]
21. Cunliffe WJ, Cobden I, Lavelle MI, Lendrum R, Tait NP, Venables CW. A randomised, prospective study comparing two contrast media in ERCP. Endoscopy 1987; 19:201-2. [AN 88054896]
22. O'Connor HJ, Ellis WR, Manning AP, Lintott DJ, McMahon MJ, Axon AT. Iopamidol as contrast medium in endoscopic retrograde pancreatography: a prospective randomised comparison with diatrizoate. Endoscopy 1988; 20:244-7. [AN 89004943]
23. Hamilton I, Lintott DJ, Rothwell J, Axon AT. Metrizamide as contrast medium in endoscopic retrograde cholangio-pancreatography. Clin Radiol 1982; 33:293-5. [AN 82185338]
24. Hannigan BF, Keeling PW, Slavin B, Thompson RP. Hyperamylasemia after ERCP with ionic and nonionic contrast media. Gastrointest Endosc 1985; 31:109-10. [AN 85205193]
25. Sherman S, Lehman GA. ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas 1991; 6:350-67. [AN 91319689]
26. May GR, Cotton PB, Edmunds SE, Chong W. Removal of stones from the bile duct at ERCP without sphincterotomy. Gastrointest Endosc 1993; 396:749-51. [AN 94123880]
27. Mathuna PM, White P, Clarke E, Merriman R, Lennon JR, Crowe J. Endoscopic balloon sphincteroplasty (papillary dilation) for bile duct stones: Efficacy, safety, and follow-up in 100 patients. Gastrointest Endosc 1995; 42:468-74. [AN 96149668]
28. Bergman JJ, Rauws EA, Fockens P, van Berkel AM, Bossuyt PM, Tijssen JG, et al. Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bile duct stones. Lancet 1997; 349:1124-9. [AN 97267680]
29. Ochi Y, Mukawa K, Kiyosawa K, Akamatsu T. Comparing the treatment outcomes of endoscopic papillary dilation and endoscopic sphincterotomy for removal of bile duct stones. J Gastroenterol Hepatol 1999; 14:90-6. [AN 99151742]
30. DiSario JA, Freeman ML, Bjorkman DJ, MacMathuna P, Petersen B, Sherman S, et al. Endoscopic balloon dilation compared to sphincterotomy (EDES) for extraction of bile duct stones: preliminary results. Gastrointest Endosc 1997; 45:AB129.
31. Siegel JH, Veerappan A, Tucker R. Bipolar versus monopolar sphincterotomy: a prospective trial. Am J Gastroenterol 1994; 89:1827-30. [AN 95029188]
32. Elta GH, Barnett JL, Wille RT, Brown KA, Chey WD, Scheiman JM. Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended current. Gastrointest Endosc 1998; 47:149-53. [AN 98171234]
33. Perini RF, Sadurski R, Hawes RH, Payne KM, Cotton PB, Cunningham JT, et al. Does the ERBE generator influence the incidence of postJOP. J Pancreas (Online) 2003; 4(1):22-32. sphincterotomy pancreatitis in patients with sphincter of Oddi dysfunction? An analysis of 560 patients. Gastrointest Endosc 2001; 53:AB61.
34. Huibregtse K, Katon RM, Tytgat GN. Precut papillotomy via fine needle-knife papillotome: a safe and effective technique. Gastrointest Endosc 1986; 32:403-5. [AN 87106619]
35. Cotton PB. Precut papillotomy: a risky technique for experts only (editorial). Gastrointest Endosc 1989; 35:578-9. [AN 90092857]
36. Foutch PG. A prospective assessment of results for needle-knife papillotomy and standard endoscopic sphincterotomy. Gastrointest Endosc 1995; 41:25-32. [AN 95212877]
37. Kasmin FE, Cohen D, Batra S, Cohen SA, Siegel JH. Needle-knife sphincterotomy in a tertiary referral center: efficacy and complications. Gastrointest Endosc 1996; 44:48-53. [AN 96433736]
38. Bruins Slot W, Schoeman MN, Disario JA, Wolters F, Tytgat GN, Huibregtse K. Needle-knife sphincterotomy as a precut procedure: a retrospective evaluation of efficacy and complications. Endoscopy 1996; 28:334-9. [AN 96408491]
39. Vandervoort J, Carr-Locke DL. Needle-knife access papillotomy: An unfairly maligned technique? Endoscopy 1996; 28:365-6. [AN 96408497]
40. Freeman ML. Precut (access) sphincterotomy. Techniques in Gastrointestinal Endoscopy. 1999; 1:40-8.
41. Sherman S, Hawes R, Earle D, Baute P, Bucksot L, Lehman G. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy (ES) -induced pancreatitis? A final analysis of a randomized prospective study. Gastrointest Endosc 1996; 43:413.
42. Rabenstein T, Schneider HT, Nicklas M, Ruppert T, Katalinic A, Hahn EG, Ell C. Impact of skill and experience of the endoscopist on the outcome of endoscopic sphincterotomy techniques. Gastrointest Endosc 1999; 50:628-36. [AN 20007795]
43. Rabenstein T, Roggenbuck S, Framke B, Martus P, Fischer B, Nusko G, et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002; 55:476-83. [AN 21920675]
44. Karalis K, Mastorakos G, Chrousos GP, Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93:2000-6. [AN 94237964]
45. Baxter JN, Jenkins SA, Day DW, Roberts NB, Cowell DC, Mackie CR, Shields R. Effects of somatostatin and a long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat. Br J Surg 1985; 72:382-5. [AN 85200606]
46. Lankisch PG, Koop H, Winckler K, Folsch UR, Creutzfeldt W. Somatostatin therapy of acute experimental pancreatitis. Gut 1977; 18:713-6. [AN 78107911]
47. Andriulli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51:1-7. [AN 20092786]
48. Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebocontrolled, randomized clinical trial. Gastrointest Endosc 2002; 56:488-95. [AN 22233811]
49. Testoni PA, Lella F, Bagnolo F, Caporuscio S, Cattani L, Colombo E, Buizza M. Long term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Pancreas 1996; 13:61-5. [AN 96377495]
50. Testoni PA, Bagnolo F, Andriulli A, Bernasconi G, Crotta S, Lella F, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001; 15:965-72. [AN 21314850]
51. Testoni PA, Cicardi M, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, et al. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc 1995; 42:301-5. [AN 96121319]
52. Ruud TE, Aasen AO, Pillgram-Larsen J, Stadaas JO. Effects on peritoneal proteolysis and haemodynamics of prophylactic infusion with C1 inhibitor in experimental acute pancreatitis. Scand J Gastroenterol 1986; 21:1018-24. [AN 87042522]
53. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariani A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscope - Italian Group. N Engl J Med 1996; 335:919-23. [AN 96365276]
54. Hajiro K, Tsujimura D, Inoue R, Yamamoto H, Yamamoto T. Effect of FOY on hyperamylasemia after endoscopic retrograde cholangiopancreatography. Gendai Iryo 1978; 10:1375-9.
55. Shimizu Y, Takahashi H, Deura M. Prophylactic effects of preoperative administration of gabexate mesilate (FOY) on post-ERCP pancreatitis. Gendai Iryo 1979; 11:540-4.
56. Masci E, Cavallini G, Mariani A, Frulloni L, Testoni PA, Curioni S, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 2003 in press.
57. Deviere J, Le Moine O, van Laethem JL, Eisendrath P, Ghilain A, Severs N, Cohard M. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120:498-505. [AN 21100083]
58. Dumot JA, Conwell DL, Zuccaro G Jr, Vargo JJ, Shay SS, Easley KA, Ponsky JL. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001; 96:2098-102. [AN 21360265]
59. Sherman S, Ruffolo TA, Hawes RH, Lehman GA. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991; 101:1068-75. [AN 91365172]
60. Sherman S, Hawes RH, Rathgaber SW, Uzer MF, Smith MT, Khusro QE, et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low and high-osmolality contrast agent. Gastrointest Endosc 1994; 40:422-7. [AN 95011329]
61. Pasha TM, Therneau T, Petersen BT. Economic analysis of gabexate mesilate in post-ERCP pancreatitis. Gastroenterology 1997; 112:A471.